Randomized Phase II Trial Comparing Docetaxel with weekly Paclitaxel and Carboplatin in Elderly Patients with Non-Small Cell Lung Cancer

Randomized Phase II Trial Comparing Docetaxel with weekly Paclitaxel and Carboplatin in Elderly Patients with Non-Small Cell Lung Cancer - DOC vs wPTX+CBDCA in Elderly NSCLC

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002616

Enrollment

Registered

2010-03-31

Start date

2008-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

Docetaxel alone Weekly paclitaxel and carboplatin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Non-small cell lung cancer Chemotherapy-naive Clinical Stage IIIB, IV, or post-operative reccurence ECOG performance status 0,1 with mesurable lesion with adequate organ function with written informed concent

Exclusion criteria

Exclusion criteria: With severe co-morbidities With symptomatic brain metastasis Pregnant female patient

Design outcomes

Primary

Measure	Time frame
Response rate	—

Countries

Japan

Contacts

Public ContactAkira Inoue

Tohoku University Hospital Department of Respiratory Medicine

akinoue@idac.tohoku.ac.jp+81-22-717-8539

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026